title: Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis.
abstract: BACKGROUND
  Fas/Fas ligand (FasL) system is one of the major pathways triggering apoptosis that has been shown to play an important role in development and pathogenesis of various diseases including liver and gastrointestinal diseases. Studies indicate that FasL deficiency provides a survival advantage in mice subjected to polymicrobial sepsis. However, the extent to which Fas/FasL contributes to organ injury during sepsis is unclear. Thus, the aim of this study was to determine whether in vivo administration of a Fas-signaling inhibitor during sepsis preserves organ function.
  
  
  METHODS
  Male adult C3H/HeN mice were subjected to cecal ligation and puncture (CLP) or sham CLP (sham). Twelve hours after CLP, mice received either Fas-receptor fusion protein (FasFP) (200 microg/kg body weight) or the saline vehicle. Twenty-four hours after the onset of sepsis, cardiac output and organ blood flow were measured with radioactive microspheres. Plasma levels of alanine aminotransferase, aspartate aminotransferase, and lactate dehydrogenase were assessed as indexes of liver damage. Changes in systemic cytokines were measured by enzyme-linked immunosorbent assay. RESULTS. The data indicate that although cardiac output and organ blood flow in the liver, intestine, kidneys, spleen, and heart decreased markedly at 24 hours after CLP, treatment with FasFP maintained the measured hemodynamic parameters and improved hepatic, intestinal, and heart blood flow (P <.05) and partially restored spleen and renal blood flow. Moreover, FasFP treatment markedly attenuated the systemic rise in alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and interleukin 10 (P <.05).
  
  
  CONCLUSIONS
  These results not only indicate that there is a role for Fas/FasL-mediated processes in the induction of organ injury but suggest that inhibition of Fas/FasL pathway may represent a novel therapeutic modality for maintaining organ perfusion and preventing liver injury during sepsis.
authors.affiliation: Surgical Research, Department of Surgery, Brown University School of Medicine and Rhode Island Hospital, Providence, RI 02903, USA.
authors.forename: C S
authors.initials: CS
authors.lastname: Chung
authors.forename: S
authors.initials: S
authors.lastname: Yang
authors.forename: G Y
authors.initials: GY
authors.lastname: Song
authors.forename: J
authors.initials: J
authors.lastname: Lomas
authors.forename: P
authors.initials: P
authors.lastname: Wang
authors.forename: H H
authors.initials: HH
authors.lastname: Simms
authors.forename: I H
authors.initials: IH
authors.lastname: Chaudry
authors.forename: A
authors.initials: A
authors.lastname: Ayala
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002432:Cecum / Q000293:injuries*; D016207:Cytokines / Q000097:blood; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008099:Liver / Q000098:blood supply / Q000378:metabolism; D008102:Liver Circulation / Q000187:drug effects / Q000502:physiology*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D011993:Recombinant Fusion Proteins / Q000494:pharmacology; D018805:Sepsis / Q000378:metabolism / Q000503:physiopathology*; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*; D019014:fas Receptor / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D016207:Cytokines; D011993:Recombinant Fusion Proteins; D019014:fas Receptor; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase